Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 12.4 USD 4.55%
Market Cap: $249.9m

Simulations Plus Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Simulations Plus Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Simulations Plus Inc
NASDAQ:SLP
Research & Development
-$8m
CAGR 3-Years
-32%
CAGR 5-Years
-20%
CAGR 10-Years
-19%
Veeva Systems Inc
NYSE:VEEV
Research & Development
-$750.1m
CAGR 3-Years
-16%
CAGR 5-Years
-22%
CAGR 10-Years
-29%
Inspire Medical Systems Inc
NYSE:INSP
Research & Development
-$103.2m
CAGR 3-Years
-15%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Research & Development
-$93m
CAGR 3-Years
-14%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Research & Development
-$87.7m
CAGR 3-Years
5%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
W
Waystar Holding Corp
NASDAQ:WAY
Research & Development
-$54.6m
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Simulations Plus Inc
Glance View

Market Cap
249.9m USD
Industry
Health Care

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.

SLP Intrinsic Value
10.43 USD
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Simulations Plus Inc's Research & Development?
Research & Development
-8m USD

Based on the financial report for Nov 30, 2025, Simulations Plus Inc's Research & Development amounts to -8m USD.

What is Simulations Plus Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-19%

Over the last year, the Research & Development growth was -26%. The average annual Research & Development growth rates for Simulations Plus Inc have been -32% over the past three years , -20% over the past five years , and -19% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett